Dasatinib plus intensive chemo versus stem cell transplant for Philadelphia chromosome positive ALL

Bookmark and Share
Published: 1 Jun 2015
Views: 2270
Dr William Slayton - University of Florida, Gainsville, USA

Dr Slayton talks to ecancertv at ASCO 2015, about the outcomes of Children's Oncology Group trial AALL0622 in patients 1-30 years old.

Treating with dasatinib plus intensive chemotherapy versus stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Results showed dasatinib with intensive chemotherapy was well tolerated; subjects with rapid response had excellent outcomes without SCT.

Further follow-up and additional trials are necessary to define the relative role of dasatinib and imatinib in promoting long-term survival in paediatric Ph positive ALL.